BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street dips as spiking crude prices revive fears of inflation, rate hike
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Morgan Stanley on BioMarin Pharmaceutical Inc. (BMRN): 'we think the settlement recognizes the value of BioMarin’s pioneering CNP innovation'
August 31, 2026 11:01 AM EDTMorgan Stanley analyst Sean Laaman reiterated an Overweight rating and $124.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).
The analyst comments "By resolving the dispute ahead of a final ITC outcome, BioMarin secures economic value now through retroactive and prospective royalties. The settlement... More
